1BAX Stock Chart & Stats
€20.52
€0.92(4.83%)
At close: 4:00 PM EDT
€20.52
€0.92(4.83%)
Day’s Range― - ―
52-Week Range€8.00 - €29.00
Previous CloseN/A
Volume0.00
Average Volume (3M)44.00
Market Cap
€10.99B
Enterprise Value€16.30K
Total Cash (Recent Filing)€2.02B
Total Debt (Recent Filing)€9.69B
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Oct 29, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding516,469,000
10 Day Avg. Volume127
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.50Price Target Upside4.77% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)1.69
Revenue Forecast (FY)€9.97B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables-driven RevenueBaxter’s core mix—IV solutions, administration sets and dialysis consumables—creates durable, recurring demand tied to patient treatments and hospital routines. This annuity-like revenue base reduces cyclicality, supports predictable cash flows, and underpins long-term installed-base economics and cross-sell opportunities.
Improving Free Cash Flow GenerationThe swing to positive free cash flow reflects better working-capital management and throughput improvements. Sustainable FCF provides a durable lever for debt repayment, targeted tuck-in M&A or selective reinvestment, improving financial optionality while earnings recover over the next few quarters.
Product Innovation And Continuous ImprovementOngoing new product introductions and AI-enabled offerings strengthen differentiation across surgery, infusion and transport. When paired with the GPS continuous-improvement program, these innovations can expand share, deepen device‑to‑consumable attachment, and support margin recovery through higher mix and efficiency gains.
Bears Say
Meaningful Leverage On The Balance SheetDebt materially exceeds equity, constraining capital allocation and elevating sensitivity to interest costs. Until margins and earnings normalize, leverage limits flexibility for growth investments or larger buybacks; management’s debt-paydown priority will absorb FCF and slow other strategic uses.
Persistent Negative Profitability And Margin CompressionSales growth has not translated into sustainable operating profits: margin pressure from tariffs, higher manufacturing costs and absorption issues keeps ROIC negative. Continued negative earnings undermine retained capital build-up and prolong the timeline to restore returns and delever the balance sheet.
Product And Supply Disruptions (Novum LVP, Injectables)Field holds, potential returns and third‑party manufacturing disruptions produce structural revenue and margin risk: they can trigger contractual penalties, inventory write‑downs and slower installed‑base adoption. These operational issues can persist into multiple quarters and impair recovery momentum.
Baxter International News
1BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was €8.00 and its highest was €29.00 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is €10.99B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Oct 29, 2026 which is in 90 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Jul 30, 2026. The company reported €0.486 earnings per share for the quarter, beating the consensus estimate of €0.319 by €0.168.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International does not currently pay dividends.
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.46.
How many shares outstanding does Baxter International have?
Baxter International has 516,469,000 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of €0.486 in its last earnings report, beating expectations of €0.319. Following the earnings report the stock price went up 4.272%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in IT:1BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€21.50 (4.77% Upside)
€21.50 (4.77% Upside)
Blogger Sentiment
Neutral
IT:1BAX Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 87%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.47%
12-Months-Change
Fundamentals
Return on Equity
0.80%
Trailing 12-Months
Asset Growth
-6.84%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
1BAX Company Deck
1BAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable operational progress (product launches, improved cash flow, continuous improvement adoption and backorder remediation) and a reiterated full-year framework against meaningful near-term financial headwinds (35% EPS decline, margin compression, Novum shipment hold and supply constraints in injectables). Management emphasized a clear turnaround plan, debt reduction priority and expected second-half recovery, but the first-half results and ongoing risks temper optimism.View all IT:1BAX earnings summaries1BAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
1BAX Stock 12 Month Forecast
Average Price Target
€21.50
▲(4.77% Upside)